摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(2,4,6-Trifluorophenyl)acrylic acid | 377084-08-7

中文名称
——
中文别名
——
英文名称
3-(2,4,6-Trifluorophenyl)acrylic acid
英文别名
(E)-3-(2,4,6-Trifluorophenyl)acrylic acid;(E)-3-(2,4,6-trifluorophenyl)prop-2-enoic acid
3-(2,4,6-Trifluorophenyl)acrylic acid化学式
CAS
377084-08-7
化学式
C9H5F3O2
mdl
——
分子量
202.133
InChiKey
JARROIJACNTGOM-OWOJBTEDSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    255.8±35.0 °C(Predicted)
  • 密度:
    1.468±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    5

文献信息

  • [EN] ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS<br/>[FR] DÉRIVÉS DE CARBOXAMIDE SUBSTITUÉS PAR ARYLE COMME INHIBITEURS DES CANAUX CALCIQUES OU SODIQUES
    申请人:RAQUALIA PHARMA INC
    公开号:WO2010137351A1
    公开(公告)日:2010-12-02
    The present invention relates to aryl substituted carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tetrodotoxin-sensitive (TTX-S)blockers such as NaV1.3 and NaV1.7, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels or voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels or voltage gated sodium channels are involved.
    本发明涉及式(I)或其药物可接受的盐的芳基取代羧酰胺衍生物,其具有T型通道或电压门控通道的阻断活性,如NaV1.3和NaV1.7等Tetrodotoxin敏感(TTX-S)阻断剂,适用于治疗或预防涉及T型通道或电压门控通道的疾病和紊乱。本发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及T型通道或电压门控通道的疾病中使用这些化合物和组合物的用途。
  • COMPOUNDS
    申请人:JIN Yun
    公开号:US20120142717A1
    公开(公告)日:2012-06-07
    The present invention relates to novel compounds that inhibit Lp-PLA 2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA 2 , for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.
    本发明涉及一种新型化合物,其抑制Lp-PLA2活性,制备这些化合物的方法,含有它们的组合物以及它们在治疗与Lp-PLA2活性相关的疾病中的应用,例如动脉粥样硬化,阿尔茨海默病和/或糖尿病黄斑肿。
  • ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS
    申请人:Inoue Tadashi
    公开号:US20120101105A1
    公开(公告)日:2012-04-26
    The present invention relates to aryl substituted carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tetrodotoxin-sensitive (TTX-S) blockers such as Na v1.3 and Na v1.7 , and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels or voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels or voltage gated sodium channels are involved.
    本发明涉及公式(I)或其药学上可接受的盐的芳基取代羧酰胺衍生物,其具有T型通道或电压门控通道的阻滞活性,如Nav1.3和Nav1.7等Tetrodotoxin敏感(TTX-S)阻滞剂,并且在涉及T型通道或电压门控通道的疾病或疾病的治疗或预防中有用。本发明还涉及包含这些化合物的制药组合物以及在涉及T型通道或电压门控通道的疾病或疾病的预防或治疗中使用这些化合物和组合物的用途。
  • PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2
    申请人:Jin Yun
    公开号:US20130252963A1
    公开(公告)日:2013-09-26
    The present invention relates to novel compounds that inhibit Lp-PLA 2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA 2 , or example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.
    本发明涉及一种新的化合物,其抑制Lp-PLA2活性,其制备过程,包含它们的组合物以及它们在治疗与Lp-PLA2活性相关的疾病中的应用,例如动脉粥样硬化,阿尔茨海默病和/或糖尿病黄斑肿。
  • SERINE RACEMASE INHIBITOR
    申请人:National University Corporation University of Toyama
    公开号:US20140371291A1
    公开(公告)日:2014-12-18
    A novel serine racemase inhibitor exhibits sufficient activity and specificity. The serine racemase inhibitor includes one or more compounds selected from compounds respectively represented by the following general formulas [MM_1], [DR_1], [DR′_1], [LW_1], and [ED_1] as an active ingredient.
    一种新型的丝氨酸外消旋酶抑制剂表现出足够的活性和特异性。该丝氨酸外消旋酶抑制剂包括一种或多种选自以下通用式[MM_1]、[DR_1]、[DR′_1]、[LW_1]和[ED_1]所代表的化合物的化合物作为活性成分。
查看更多